Singapore — As global pharmaceutical companies grapple with soaring R&D costs, long development timelines and rising clinical failure rates, a new generation of Singapore-based biotech firms is positioning artificial intelligence as a structural solution rather than a technological add-on. Among them is Nanyang Biologics, a home-grown deep-tech company that has been quietly building an AI-native … Continue reading Singapore bets on AI-driven drug discovery as Nanyang Biologics pushes the frontiers of biotech